Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.08Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 11.11%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong operational progress and strategic investments offset by challenges in key markets and regulatory hurdles. The company's confidence in overcoming these challenges and achieving breakeven by the end of 2025 provides a cautiously optimistic outlook.Company Guidance
During the CytoSorbents' first quarter 2025 earnings call, several key metrics and guidance were provided. The company reported product sales of $8.7 million, a 3% year-over-year decline, although sales were flat when adjusted for constant currency. Gross margin remained steady at 71%, consistent with the 2024 average. The company aims to return its German sales to growth in the second half of 2025, following a strategic reorganization of its sales team. CytoSorbents reiterated its goal to approach breakeven by the end of 2025, supported by sufficient cash to fund initiatives. Additionally, CytoSorbents is preparing for the potential commercial launch of DrugSorb-ATR in the U.S. and Canada, with an initial market opportunity estimated at over $300 million. The company is pursuing an appeal process with the FDA after receiving a denial letter for DrugSorb-ATR, while also awaiting regulatory decisions from Health Canada.Solid Gross Margin Performance
The company maintained a gross margin of 71%, consistent with the 2024 average, despite a decrease in production volume.
Progress Toward Breakeven
The company is making meaningful operational progress, moving steadily towards near breakeven by the second half of 2025.
Positive International Sales Performance
Strong performances in international distribution and other direct sales markets helped offset temporary disruptions in the German market.
Successful Fundraising
The company raised $6.8 million through a shareholder rights offering and released $5 million of restricted cash, increasing available liquidity by $11.8 million.
New Leadership in Marketing
Tom Shannon joined as Vice President of Marketing for North America, bringing over 25 years of experience to support the potential launch of DrugSorb-ATR.
Promising Regulatory Path for DrugSorb-ATR
Despite a denial letter from the FDA, the company is confident in its appeal process for DrugSorb-ATR, citing strong data and potential resolution of remaining issues.
---
CTSO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CTSO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $0.81 | $0.83 | +2.47% |
Mar 31, 2025 | $1.00 | $1.00 | 0.00% |
Nov 07, 2024 | $0.90 | $0.74 | -17.78% |
Aug 13, 2024 | $0.90 | $0.97 | +7.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cytosorbents Corp (CTSO) report earnings?
Cytosorbents Corp (CTSO) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Cytosorbents Corp (CTSO) earnings time?
Cytosorbents Corp (CTSO) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTSO EPS forecast?
CTSO EPS forecast for the fiscal quarter 2025 (Q2) is -0.04.
---